$KTTA 1.12 on the move $694,000 of non-dilutive funding received https://finance.yahoo.com/news/pasithea-therapeutics-awarded-drug-development-120000603.html https://stockcharts.com/c-sc/sc?s=KTTA&p=W&yr=1&mn=10&dy=0&i=t1259487640c&r=1658339632055 NASDAQ 13.2M O/S https://www.otcmarkets.com/stock/KTTA/security $52M cash on hand versus $25M market cap. Trading below cash value. CEO exercised options to add 200k shares at $1.44. Insiders (34.5%) shares are locked up til March. No risk of dumping. Average share cost from retail is $4.53. https://www.pasithea.com https://www.pasithea.com/wp-content/uploads/2021/03/Pasithea_Full_Logo.svg